English
Our history
A French specialty pharma story
An entrepreneurial journey from inspiration to innovation.
Juvisé Pharmaceuticals is a family-owned pharmaceutical company with over 15 years of experience
Inspiration
From LynaPharm to Juvisé Pharmaceuticals.
In 2002, Frédéric Mascha was a French entrepreneur with extensive pharmaceutical experience gained from several years as an Associate Principal at a leading strategy consulting firm, where he worked in both Europe and the United States.
He observed a growing trend of U.S. companies being created as “Specialty Pharma” to acquire mature drugs divested by major pharmaceutical companies that were looking to refocus on their pipelines or other therapeutic areas.
He seized the opportunity with his first acquisition, a psychiatric drug from Pfizer, to found LynaPharm, a pharmaceutical company specializing in neuropsychiatry, in joint venture with the Italian pharmaceutical group Sigma-Tau.
Later, LynaPharm acquired the rights to two additional psychiatric drugs from Novartis and Astellas before being acquired by the Sigma-Tau group in 2008.
Inception and industry innovation
Juvise Pharmaceuticals: a European specialty pharma company.
After the success of LynaPharm, Frédéric Mascha funded Juvisé Pharmaceuticals in 2008.
In over 16 years, Juvisé Pharmaceuticals has grown and developed, acquiring princeps drugs in new therapeutic areas, from neuropsychiatry and cardiology to oncology, gastroenterology and neurology.
Juvisé Pharmaceuticals’ objective remains to identify and then acquire drugs recognized by the medical community for their therapeutic value. Once secured, we ensure their manufacturing, distribution, and marketing, making them available to 2.5 million patients each year.
Our ambition is to keep protecting patients’ health by providing them access to effective treatments that significantly improve their disease condition.
To this end, over the next few years, we will focus on becoming the preferred European commercial partner for research and major pharmaceutical companies worldwide.
Our History at a glance
Frédéric MASCHA creates Juvisé Pharmaceuticals
Frédéric MASCHA creates Juvisé Pharmaceuticals
Juvisé Pharmaceuticals acquires Lumirelax® (Thera France) and Extovyl® (Thera France)
Juvisé Pharmaceuticals acquires Lumirelax® (Thera France) and Extovyl® (Thera France)
Juvisé Pharmaceuticals acquires Entumin® (Novartis), Insidon® (Thera France) and Calmixène® (Thera France)
Juvisé Pharmaceuticals acquires Entumin® (Novartis), Insidon® (Thera France) and Calmixène® (Thera France)
Juvisé Pharmaceuticals takes in license Proxeed Plus® (Sigma-Tau), Ezerex® (Sigma-Tau)
Juvisé Pharmaceuticals takes in license Proxeed Plus® (Sigma-Tau), Ezerex® (Sigma-Tau)
Juvisé Pharmaceuticals acquires Esidrex® (Novartis), Sintrom® (Novartis) and Digoxine-Juvisé® (Novartis)
Juvisé Pharmaceuticals acquires Esidrex® (Novartis), Sintrom® (Novartis) and Digoxine-Juvisé® (Novartis)
Juvisé Pharmaceuticals acquires Arimidex® (AstraZeneca) and Casodex® (AstraZeneca)
Juvisé Pharmaceuticals acquires Arimidex® (AstraZeneca) and Casodex® (AstraZeneca)
Juvisé Pharmaceuticals acquires Pylera® (Abbvie)
Juvisé Pharmaceuticals acquires Pylera® (Abbvie)
Juvisé Pharmaceuticals acquires Ponvory® (Johnson & Johnson Innovative Medicine)
Juvisé Pharmaceuticals acquires Ponvory® (Johnson & Johnson Innovative Medicine)
JUV-FRA-202408-0213, 09/2024
More about Juvisé Pharmaceuticals
From neuroscience to gastroenterology, our medications treat 2.5 million patients each year
Join Juvisé Pharmaceuticals and become part of a company that values excellence and commitment
From neuroscience to gastroenterology, our medications treat 2.5 million patients each year
Join Juvisé Pharmaceuticals and become part of a company that values excellence and commitment